Literature DB >> 31169760

Quality Assessment of Dried Blood Spots from Patients With Tuberculosis from 4 Countries.

Marlanka A Zuur1, Herman Veenhof1, Alena Aleksa2, Natascha Vanʼt Boveneind-Vrubleuskaya3, Endang Darmawan4, Md Golam Hasnain5,6, Scott K Heysell7, Erwin M Jongedijk8, Remco A Koster8,9, Cecile Magis-Escurra10, Nilza Martinez11, Gladys Molinas11, Dinesh Mondal5, Ully A Mulyani12, Dyah A Perwitasari4, Andrej Tsivunchyk2, Daan J Touw1,8, Jan-Willem C Alffenaar1,13,14.   

Abstract

BACKGROUND: Dried blood spot (DBS) sampling is a blood collection tool that uses a finger prick to obtain a blood drop on a DBS card. It can be used for therapeutic drug monitoring, a method that uses blood drug concentrations to optimize individual treatment. DBS sampling is believed to be a simpler way of blood collection compared with venous sampling. The aim of this study was to evaluate the quality of DBSs from patients with tuberculosis all around the world based on quality indicators in a structured assessment procedure.
METHODS: Total 464 DBS cards were obtained from 4 countries: Bangladesh, Belarus, Indonesia, and Paraguay. The quality of the DBS cards was assessed using a checklist consisting of 19 questions divided into 4 categories: the integrity of the DBS materials, appropriate drying time, blood volume, and blood spot collection.
RESULTS: After examination, 859 of 1856 (46%) blood spots did not comply with present quality criteria. In 625 cases (34%), this was due to incorrect blood spot collection. The DBS cards from Bangladesh, Indonesia, and Paraguay seemed to be affected by air humidity, causing the blood spots not to dry appropriately.
CONCLUSIONS: New tools to help obtain blood spots of sufficient quality are necessary and environmental specific recommendations to determine plasma concentration correctly. In addition, 3% of the DBS cards were rejected because the integrity of the materials suggesting that the quality of plastic ziplock bags currently used to protect the DBS cards against contamination and humidity may not be sufficient.

Entities:  

Year:  2019        PMID: 31169760     DOI: 10.1097/FTD.0000000000000659

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  3 in total

1.  Effects, costs and implementation of monitoring kidney transplant patients' tacrolimus levels with dried blood spot sampling: A randomized controlled hybrid implementation trial.

Authors:  Herman Veenhof; Job Frank Martien van Boven; Anna van der Voort; Stefan Philip Berger; Stephanus Johannes Leonardus Bakker; Daniël Johannes Touw
Journal:  Br J Clin Pharmacol       Date:  2020-02-28       Impact factor: 4.335

2.  Pharmacodynamic biomarkers for quantifying the mycobacterial effect of high doses of rifampin in patients with rifampin-susceptible pulmonary tuberculosis.

Authors:  Bibie N Said; Scott K Heysell; Getnet Yimer; Rob E Aarnoutse; Gibson S Kibiki; Stellah Mpagama; Peter M Mbelele
Journal:  Int J Mycobacteriol       Date:  2021 Oct-Dec

3.  Best Practices to Implement Dried Blood Spot Sampling for Therapeutic Drug Monitoring in Clinical Practice.

Authors:  Marith I Francke; Laura E J Peeters; Dennis A Hesselink; Sanne M Kloosterboer; Birgit C P Koch; Herman Veenhof; Brenda C M de Winter
Journal:  Ther Drug Monit       Date:  2022-05-23       Impact factor: 3.118

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.